Mary Kay Continues Its Commitment to Skin Science
13.1.2022 16:03:00 EET | Business Wire | Press release
Mary Kay Inc., one of the world’s innovative skincare companies, participated at two renowned European conferences in late 2021. At the 19th Aesthetic & Anti-Aging Medicine World Congress, Mary Kay Inc. submitted a scientific poster on the usage and tolerability of a highly concentrated retinol formula in Asian skin. Mary Kay Inc. also partnered with the European Society’s Dermatological Research (ESDR) in sponsoring Future Leaders in Dermatology Symposium at their 50th Annual conference. At this conference, Mary Kay Inc. shared the results of a recent clinical study that demonstrated the capability of a cosmetic formulation to alleviate symptoms associated with sensitive skin.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220113005071/en/
Dr. Lucy Gildea, Mary Kay Chief Innovation Officer, Product and Science (Photo: Mary Kay Inc.)
The 19th Aesthetic & Anti-Aging Medicine World Congress took place from September 16-18, 2021, in Monte Carlo and was held under the High Patronage of H.S.H. Prince Albert II of Monaco. Attendees of this conference extended to several professions including dermatologists, plastic and cosmetic surgeons, anti-aging doctors, and aesthetic and general practitioners. Over 8,300 participants from 130 countries joined the conference, both in-person and virtually. The digital platform offered an immersive virtual experience that complemented the physical show allowing attendees to join the digital exhibition and watch workshops regardless of the distance or travel restrictions.
Mary Kay scientists were proud to share their latest research on retinol use and tolerability at this conference. By using a gradual retinization protocol on Asian individuals, there was an improvement in their overall skin appearance as well as a reduction in post-inflammatory hyperpigmentation - a common concern when using retinol, especially in skin of color.
“Retinol is a gold-standard skincare ingredient with many proven benefits, but the experience and tolerability of a retinol product are not the same for every person. For individuals who are concerned about potential irritation or hyperpigmentation, the results of this study offer potential solutions. I am very excited to share this research with the scientific community worldwide at AMWC’s 19th World Congress to share our innovative research with professionals in skin science and aging,” said Dr. Lucy Gildea, Chief Scientific Officer at Mary Kay Inc.
“AMWC 2021 featured a multi-faceted aesthetic and anti-aging medicine program aimed at promoting high-level continued education and we were happy to have Mary Kay participate this year. We hope that we have succeeded in helping to inspire the exchange of new ideas and the sharing of ‘know-how’ in this field on a global level”, said Catherine Decuyper, EuroMediCom Founder and President. “I am grateful to our team, our global partners, the attendees, and the scientific community at large for their contributions and for the opportunity to serve them and their aesthetic and anti-aging medicine needs.”
Following the success of AMWC 2021, EuroMediCom will host AMWC 2022 from March 31 to April 2, 2022, in a hybrid format again in order to allow delegates from across the world to join them for the 20th edition of their world-leading aesthetic and anti-aging medicine congress. Registrants can choose to attend in person or watch live-streamed sessions from anywhere in the world.
The annual European Society’s Dermatological Research (ESDR) Conference is held in Europe each year every September. In 2021, due to travel restrictions and COVID-19 precautions, the annual meeting took place entirely virtually from September 22-15, 2021. ESDR supports investigative dermatology with the goal of improving the health of patients who are suffering from various skin and infectious diseases and immune disorders. In addition to presenting research, Mary Kay was also able to sponsor a Future Leaders in Dermatology symposium that kicked off the conference.
Associate Principal Scientist Geetha Kalahasti at Mary Kay Inc. shared the results of a recent clinical study that evaluated the effects of a new formulation that contained a blend of lipids identical to the skin's natural ratio, a nociceptor (TRPV-1) antagonist, and a botanical extract that reduces the expression of proinflammatory cytokines.
“At Mary Kay, we are committed to understanding skin biology and designing new products that address skin needs. One ongoing area of focus has been the relationship between sensitive skin and skin barrier function,” said Kalahasti. “Each of these materials targeted a specific biological pathway that contributes to skin redness. The findings revealed that this multi-faceted approach helps strengthen the compromised skin barrier and alleviate discomfort associated with sensitive skin.”
“On behalf of the ESDR board, we would like to thank Mary Kay for the support of the ESDR and the generous contribution to ESDR activities. One of the most important activities of our Society is to promote the presentation of new research data and ideas, and we are delighted to have Mary Kay be a part of this event,” said Leopold Eckhart, Chair, Scientific Program Committee of ESDR.
This particular symposium helps connect young researchers with renowned scientists in dermatology and encourages such collaborations – a focus that is very important to Mary Kay Inc.
ABOUT MARY KAY
One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey to economic independence through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn or follow us on Twitter.
ABOUT EUROMEDICOM
EuroMediCom, created in 1999 and part of Informa Exhibitions since 2010, is dedicated to promoting Life Sciences and knowledge through educational Trainings, Conferences & Exhibitions. The main event, AMWC was created in 2003 and has since become the largest and leading medical aesthetic congress in the world. AMWC was developed with the strong belief that external aesthetic treatments and internal aging prevention could be comprehensively addressed by integrating two aspects: aesthetics strategy through dermatology and surgery procedures for external appearance and anti-aging medicine for prevention of aging and enhancement of aesthetic treatments. For more information about AMWC, click here: https://www.euromedicom.com/en/home.html
ABOUT THE EUROPEAN SOCIETY DERMATOLOGICAL RESEARCH (ESDR)
The European Society for Dermatological Research (ESDR), founded in 1970, is a non-profit organization promoting basic and clinical science related to dermatology. The ESDR is the largest investigative dermatology society in Europe with a current membership of about 1100. By supporting investigative dermatology and skin research, the ESDR contributes to an in-depth understanding of skin homeostasis and towards improving the health of patients suffering from skin and venereal disease, infectious diseases, and immune-mediated and inflammatory disorders. The ESDR facilitates exchange of information relevant to investigative dermatology between clinicians and scientists worldwide. The ESDR also organizes educational events throughout the year to further knowledge in dermatological research. For more information, please visit: https://esdr.org/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220113005071/en/
Contact information
Mary Kay Inc. Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Great Britain Leads Europe’s FMCG Inflation as NIQ Launches New Inflation Barometer6.8.2026 10:00:00 EEST | Press release
NIQ (NYSE: NIQ) today launches its new EU5 FMCG Inflation Barometer - a monthly tracker across five Western Europe markets – France, Great Britain, Germany, Italy and Spain – designed to help retailers, manufacturers and the media understand how inflation is evolving across Europe’s largest grocery markets and how shoppers are responding. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806579111/en/ EU5 CPG Inflation slows to +1.1% The first edition of the Barometer reveals that while inflation across Europe’s FMCG sector remains relatively contained overall, significant differences persist between countries. Key findings include: Great Britain recorded the highest FMCG inflation across the EU5 at +2.3%1, above the European average of +1.1%. France and Italy reported the lowest inflation at -0.4% and +0.6% retrospectively, highlighting the uneven inflationary landscape across Europe's major economies. The monthly Barometer
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN ® APN6.8.2026 07:30:00 EEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom